Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir/lamivudine vs bictegravir/emtricitabine/tenofovir alafenamide in treatment-naive adults with HIV
jRCT2051230132Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Dolutegravir/lamivudine with Bictegravir/emtricitabine/tenofovir alafenamide (2 arms). Primary endpoint: Virologic suppression at Week 48. Started Dec 2023; status: active, not recruiting.
02
Drugs
dolutegravirlamivudinebictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2051230132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230132.